Clinical Trials Logo

Lobular Breast Carcinoma in Situ clinical trials

View clinical trials related to Lobular Breast Carcinoma in Situ.

Filter by:

NCT ID: NCT04496739 Recruiting - Clinical trials for Lobular Breast Carcinoma In Situ

Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)

Start date: October 23, 2020
Phase: N/A
Study type: Interventional

This trial studies the implementation of web-based decision support tools for patients with atypical hyperplasia or lobular carcinoma in situ and healthcare providers. Decision support tools are designed to improve informed choice about breast cancer chemoprevention. Recognizing barriers and facilitators that can influence the adoption of decision support tools at recruitment centers may help researchers learn how to best implement them into clinical practice.

NCT ID: NCT02961790 Completed - Breast Carcinoma Clinical Trials

Oxybutynin Chloride in Managing Hot Flashes

Start date: December 9, 2016
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies how well oxybutynin chloride works in managing hot flashes in patients who are not candidates for, or not interested in hormone replacement therapy. Previous studies have shown that oxybutynin is effective in managing hot flashes, however doses used in prior studies have resulted in side effects. This trial is evaluating lower doses of oxybutynin with the goal of determining if they are efficacious with less side effects. ADAM-VTE

NCT ID: NCT02515110 Active, not recruiting - Breast Cancer Clinical Trials

Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer

Start date: August 4, 2015
Phase: N/A
Study type: Interventional

Single-arm, phase 2 study evaluating hypofractionated irradiation of breast and regional nodes in women with breast cancer. Patients will be grouped in 3 surgery-related treatment groups: 1) An intact breast following lumpectomy; 2) plans for loco regional external beam radiotherapy (EBRT) following mastectomy (with or without plans for reconstruction); and 3) plans for locoregional EBRT following mastectomy with reconstruction. Patients will be assessed for lymphedema, arm function, breast or chestwall pain, other EBRT-related adverse events, and, for patients who had a lumpectomy or mastectomy with reconstruction, cosmetic outcome.

NCT ID: NCT02314156 Completed - Clinical trials for Stage IB Breast Cancer

Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy

Start date: October 2015
Phase: Phase 2
Study type: Interventional

This randomized trial studies transdermal or oral telapristone acetate in treating patients undergoing surgery to remove the breast (mastectomy). Telapristone acetate may help prevent breast cancer from forming in premenopausal women. Giving telapristone acetate transdermally may be safer and have fewer side effects than oral administration.

NCT ID: NCT01975363 Completed - Clinical trials for Ductal Breast Carcinoma in Situ

Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer

Start date: June 2013
Phase: N/A
Study type: Interventional

This randomized pilot clinical trial studies a nanoemulsion formulation of curcumin in reducing inflammatory changes in breast tissue in obese women at high risk for breast cancer. Curcumin may reduce inflammation in breast tissue and fat. This may affect the risk of developing breast cancer.

NCT ID: NCT01905046 Active, not recruiting - Clinical trials for Ductal Breast Carcinoma in Situ

Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer

Start date: November 23, 2015
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies metformin hydrochloride to see how well it works compared to placebo in preventing breast cancer in patients with atypical hyperplasia or in situ breast cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of metformin hydrochloride may prevent breast cancer.

NCT ID: NCT01874184 Completed - Clinical trials for Ductal Breast Carcinoma in Situ

Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer

DEEM
Start date: October 2013
Phase: N/A
Study type: Interventional

This randomized clinical trial studies a group-based lifestyle intervention or usual care in measuring biomarker levels in participants at high risk for breast cancer. Studying the effects that changes to daily eating and exercise habits can have on the body's hormone levels and the body's ability to activate proteins may help doctors identify interventions for individuals at high risk for breast cancer.

NCT ID: NCT01869764 Completed - Clinical trials for Stage IIIA Breast Cancer

Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer

Start date: November 2013
Phase: Phase 2
Study type: Interventional

This phase II clinical trial studies how well omega-3 fatty acid works in treating patients with stage I-III breast cancer. Studying samples of tissue and blood in the laboratory from breast cancer patients receiving omega-3 fatty acid may help doctors learn more about the effects of omega-3 fatty acid on tumor cells.

NCT ID: NCT01849250 Completed - Clinical trials for Stage IIIA Breast Cancer

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

Start date: May 2013
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well docosahexaenoic acid works in preventing recurrence in breast cancer survivors. Docosahexaenoic acid supplement may prevent recurrence in breast cancer survivors.

NCT ID: NCT01819233 Completed - Clinical trials for Recurrent Breast Cancer

Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy

CAREFOR
Start date: March 8, 2013
Phase: N/A
Study type: Interventional

This pilot clinical trial studies caloric restriction in patients with stage 0-I breast cancer during surgery and radiation therapy. Reducing caloric intake may prevent disease progression in patients with breast cancer. Radiation therapy uses high energy x rays to kill tumor cells. Giving dietary intervention and radiation therapy together may kill more tumor cells.